GLP-1 medication a novel treatment for binge eating disorders
New systematic review reveals GLP-1 medication as a novel treatment for binge eating disorders

GLP-1 medication a novel treatment for binge eating disorders
New systematic review reveals GLP-1 medication as a novel treatment for binge eating disorders: Insights from Calle Mauritzson, Licensed Psychologist at Yazen.
A new study, published in the Journal of Clinical & Translational Endocrinology, has shown that treatment with GLP-1 medication is a promising novel approach for binge eating disorder and bulimia nervosa. Calle Mauritzson, licensed psychologist at the healthcare provider Yazen, provides his perspective on why the integration of GLP-1 medication in the treatment of these conditions seems so effective.
1. New understanding of binge eating and medical mechanisms: It’s crucial for care givers to understand how GLP-1 receptor agonists work. These medications can significantly reduce binge eating episodes by influencing the brain's appetite-regulating pathways, which helps in managing the disorder more effectively.
2. Regular meals with the aid of medicine: Combining regular meal patterns with the use of GLP-1 receptor agonists is essential. This approach helps stabilise appetite and prevent binge eating episodes, creating a structured eating routine that supports recovery.
3. Identify triggers and use medication as support: Using GLP-1 receptor agonists can reduce the physical urge to binge eat. Simultaneously, it's important for patients to work on identifying and managing their personal triggers and creating a comprehensive treatment plan.
4. Cognitive change and medication: Cognitive treatment becomes more effective when combined with medical treatment. GLP-1 receptor agonists can lessen the physical cravings, making it easier for patients to implement cognitive strategies and change negative thought patterns.
5. Alternative coping strategies and weight loss: Developing healthy coping strategies is vital. With the help of GLP-1 receptor agonists, patients can manage weight loss and improve their relationship with food, facilitating a healthier lifestyle
6. Physical activity with medical monitoring: Incorporating regular physical activity is an important part of the treatment plan. We need to consider the effects of GLP-1 receptor agonists on appetite and energy levels to tailor the physical activity to each patient’s needs."
7. Support network and medical treatment: A strong support network is invaluable. Emotional support from friends, family, or support groups, combined with the physiological benefits of GLP-1 receptor agonists, can greatly enhance the treatment process.
This comprehensive approach, integrating both medical treatment and behavioural strategies, provides a more effective and holistic treatment for patients struggling with binge eating disorder and bulimia nervosa.
Read the interesting review:
https://www.sciencedirect.com/science/article/pii/S2214623724000048

October 14, 2024
May 19, 2026
Start your weight loss journey with Yazen today
Everything you need to do is to create an account and answer some questions about your health
More articles
Trulicity and Medical Weight Loss: How Treatment with Dulaglutide Works
Trulicity is a prescription medication containing the active substance dulaglutide. It belongs to the group of GLP-1 receptor agonists and is used for the treatment of type 2 diabetes.
Dulaglutide mimics the effect of the body's own hormone GLP-1, which helps regulate blood sugar. The medication can also affect appetite and satiety, which can lead to some weight loss.
Beyond GLP-1 medicines: the path to successful and long-term weight loss
We are in a new era of obesity treatment. GLP-1-based medicines have transformed the landscape – but real success is achieved when medication becomes part of a comprehensive approach that supports the whole person.
Long-term health and weight loss require more than medicine alone. It is when medical treatment is combined with lifestyle change and continuous guidance that meaningful, lasting progress becomes possible (1–2).





